Prednisone 5mg / 10mg / 20mg (Deltasone Generic)
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Prednisone 5mg / 10mg / 20mg (Deltasone Generic). Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
📖 Peer-Reviewed Clinical Monograph1. Pharmacological Profile & Executive Summary
Potent systemic glucocorticoid pro-drug that converts in the liver to prednisolone, suppressing pro-inflammatory cytokine transcription in severe autoimmune and inflammatory conditions.
Rheumatology & Internal Therapeutics • Prednisone 5mg / 10mg / 20mg (Deltasone Generic)
2. Human Pharmacokinetic Matrix
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | 1.0 to 2.0 hours | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 2.5 to 3.5 hours (plasma); tissue biological effect lasts 18–36 hours | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | Dose-dependent | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | 80% to 100% | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 70% to 90% (bound to transcortin and albumin) | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | 0.6 to 0.8 L/kg | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | Hepatic 11-beta-HSD1 reduction to active prednisolone, followed by CYP3A4 | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | Excreted primarily in urine as sulfate and glucuronide conjugates | Renal vs biliary/fecal excretion balance. |
3. Evidence-Based Clinical Dosing Protocols
Daily / Baseline Regimen
Acute Inflammatory Flares / Asthma Exacerbation: 20 mg to 60 mg daily for 5 to 7 days (burst therapy). Chronic Autoimmune Maintenance: 5 mg to 10 mg once daily in the morning.
On-Demand / Titration Regimen
Always take in the early morning with breakfast to mimic the body's natural circadian cortisol peak and prevent insomnia.
Courses lasting >2 weeks require a gradual dose taper to prevent secondary adrenal insufficiency.
4. Pharmacokinetic Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| NSAIDs (Ibuprofen, Naproxen) | Major Precaution | Synergistic increase in peptic ulceration and gastrointestinal bleeding. |
| Antidiabetic Agents / Insulin | Dose Adjustment | Glucocorticoids induce hepatic gluconeogenesis and elevate blood glucose. |
5. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Insomnia & Increased Energy | 20% | Mitigated by taking entire dose in the morning before 09:00 AM. |
| Increased Appetite & Fluid Retention | 15% | Cortisol-mediated metabolic response. |
| Hyperglycemia | 12% | Transient insulin resistance. |
6. Patient Administration & Safe Usage Guidelines
Take with breakfast or milk. Never stop abruptly if you have been taking prednisone for more than 14 days; follow a gradual taper.
7. Frequently Asked Clinical Questions
Why must Prednisone be taken in the morning?
Human adrenal cortisol production peaks naturally between 06:00 and 08:00 AM. Morning administration synchronizes with this circadian rhythm, minimizing pituitary-adrenal suppression and insomnia.
How does Prednisone convert to Prednisolone?
Prednisone is an inactive pro-drug. The hepatic enzyme 11-beta-hydroxysteroid dehydrogenase type 1 converts it into biologically active prednisolone within 1 hour.
Verified Telehealth Access Standards for Prednisone 5mg / 10mg / 20mg (Deltasone Generic)
Our clinical editorial board audits certified partner telehealth dispensaries to guarantee authentic WHO-GMP manufacturing, analytical batch testing, and physician-supervised asynchronous consultation.
Peer-Reviewed Scientific Citations & FDA References
- Fardet L, et al. Corticosteroid-induced adverse events: a review. Drug Saf. 2007;30(10):861-881.